



Back to Work program implementation guide

Working together,
we can help provide
clarity in the face
of uncertainty



Helping you and your staff get back to workplace productivity

The Quest Diagnostics **Back to Work program** helps your employees manage their risk of SARS-CoV-2 (COVID-19) exposure in order to support a return to work.

This implementation guide leads you through the step-by-step process for establishing the program, and outlines the roles and expectations for you, your employees, and Quest Diagnostics.

For more information on COVID-19, please visit [QuestDiagnostics.com/COVID-19](https://www.questdiagnostics.com/COVID-19)

Our Back to Work solution can help you:

- Follow federal and state health and safety guidelines
- Keep doors open during the pandemic
- Help speed up time to return productivity back to pre-pandemic levels
- Instill confidence in employees that they work for an employer dedicated to employee health and safety
- Strengthen your reputation in the community as an employer of choice that is committed to employee well-being even during times of crisis

How the **Back to Work program** works

We've developed a standard approach that can serve as an example for helping employees get back to the workplace. Every organization has different challenges and needs—and we work with every organization to develop the approach that's right for them.



Participant will provide sample for SARS-CoV-2 (COVID-19) molecular testing either at a retail partner convenient to the employee's home or via an authorized retail location.

- If result is positive, do not allow employee to return to work and connect to next steps of care
- Decisions to allow workers with COVID-19 to return to work may follow either a symptom-based, time-based, or test-based strategy

- Employees are **alerted via email** when test results are ready
- MyQuest uses patient-friendly terms to help interpret the results
- Results can be printed or shared via email

Create MyQuest™ account



Each participant will be encouraged to **sign up for a MyQuest** account.

This free and secure portal allows participants to easily view their test results online and schedule appointments at Patient Service Centers (PSCs).

Getting tested



- Depending on the program selected by the organization, the employee could **schedule an appointment at a PSC** for a SARS-CoV-2 (COVID-19) Antibody Immunoglobulin G (IgG) test

Result returned via MyQuest®




Report back to organization



Employer administrators can **review and verify employee participation** status and results through MyQuest.

- Daily email reports display program engagement and results



The antibody tests (sometimes known as the serology tests or IgG tests) are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. The antibody test should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the antibody test may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

- The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
- All tests have been authorized by FDA under EUAs for use by authorized laboratories;
- The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
- The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and,
- All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Image content used for illustrative purposes only. Person depicted in the content is a model.

[QuestDiagnostics.com](https://www.questdiagnostics.com)

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2020 Quest Diagnostics Incorporated. All rights reserved. SB9754 10/2020